Clinical Trials Directory

Trials / Conditions / Advanced or Metastatic Breast Cancer

Advanced or Metastatic Breast Cancer

15 registered clinical trials studyying Advanced or Metastatic Breast Cancer — 3 currently recruiting.

StatusTrialSponsorPhase
CompletedA Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palboc
NCT06962969
Pfizer—
Not Yet RecruitingThe Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Brea
NCT06934733
Henan Cancer HospitalN/A
RecruitingEvaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Meta
NCT06201234
GBG Forschungs GmbHPhase 2
Active Not RecruitingA Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR
NCT06105632
PfizerPhase 2
TerminatedMilademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer
NCT05932667
Institut CuriePhase 2
RecruitingA Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
NCT05187832
Kind Pharmaceuticals LLCPhase 1
CompletedPelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
NCT05519059
Adlai Nortye Biopharma Co., Ltd.Phase 1
UnknownA Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)
NCT04742153
Shanghai Miracogen Inc.Phase 2
Active Not RecruitingStudy of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Po
NCT04494425
AstraZenecaPhase 3
CompletedMEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
NCT03767335
Menarini GroupPhase 1
CompletedPhase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
NCT01676753
Jo ChienPhase 1
CompletedDose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopa
NCT02154776
Novartis PharmaceuticalsPhase 1
CompletedInvestigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Pati
NCT01625286
AstraZenecaPhase 1 / Phase 2
CompletedSafety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Sc
NCT01226316
AstraZenecaPhase 1
CompletedA Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Brea
NCT00748553
University of UtahPhase 1 / Phase 2